Stockscreener 앱 받기
76.06
3.72%
2.73
시간 외 거래:
76.50
0.44
+0.58%
전일 마감가:
$73.33
열려 있는:
$84.845
하루 거래량:
9.16M
Relative Volume:
3.67
시가총액:
$14.58B
수익:
$353.78M
순이익/손실:
$-805.69M
주가수익비율:
-18.17
EPS:
-4.1869
순현금흐름:
$-597.61M
1주 성능:
+19.35%
1개월 성능:
-1.02%
6개월 성능:
+54.94%
1년 성능:
+138.06%
1일 변동 폭
$76.03
$84.94
1주일 범위
$67.59
$84.94
52주 변동 폭
$28.32
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
명칭
Bridgebio Pharma Inc
전화
(650) 391-9740
주소
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
76.06 | 14.05B | 353.78M | -805.69M | -597.61M | -4.1869 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2026-01-06 | 개시 | Morgan Stanley | Overweight |
| 2025-12-11 | 개시 | Bernstein | Outperform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-14 | 개시 | Jefferies | Buy |
| 2025-07-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-03 | 개시 | Oppenheimer | Perform |
| 2024-09-04 | 개시 | Piper Sandler | Overweight |
| 2024-03-21 | 재개 | Raymond James | Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Market Perform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-07 | 개시 | Citigroup | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-19 | 개시 | Evercore ISI | Outperform |
| 2023-02-06 | 개시 | Cowen | Outperform |
| 2021-12-27 | 재확인 | Mizuho | Buy |
| 2021-12-27 | 재확인 | SVB Leerink | Outperform |
| 2021-09-10 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-03-22 | 재확인 | Goldman | Buy |
| 2021-02-22 | 재개 | JP Morgan | Overweight |
| 2021-02-09 | 재개 | Goldman | Buy |
| 2021-01-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Neutral |
| 2020-05-19 | 개시 | BTIG Research | Buy |
| 2020-04-13 | 개시 | H.C. Wainwright | Buy |
| 2020-02-19 | 개시 | Mizuho | Buy |
| 2019-07-26 | 개시 | Raymond James | Outperform |
| 2019-07-22 | 개시 | BMO Capital Markets | Outperform |
| 2019-07-22 | 개시 | Goldman | Buy |
| 2019-07-22 | 개시 | JP Morgan | Overweight |
| 2019-07-22 | 개시 | Jefferies | Buy |
| 2019-07-22 | 개시 | Piper Jaffray | Overweight |
| 2019-07-22 | 개시 | SVB Leerink | Outperform |
모두보기
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
Dwarfism golden gate? Bridgebio’s infigratinib phase III hits - BioWorld MedTech
BridgeBio Announces Positive Phase 3 Achondroplasia Trial Results - TipRanks
Dwarfism meds 'miraculously' took kids who started at a low growth baseline to typical height velocity: BridgeBio Pharma CEO - Fox Business
BridgeBio Pharma shares rise on ‘compelling’ Phase 3 trial results for achondroplasia drug - Proactive financial news
BridgeBio reports positive phase 3 topline results for oral infigratinib - marketscreener.com
BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing - MedCity News
BridgeBio's oral drug improves growth in children with dwarfism in late-stage study - marketscreener.com
BBIO Stock Surges 17% Pre-Market Today – What’s Fueling The Rally? - Stocktwits
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - bitget.com
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Benzinga
BridgeBio (BBIO) Surges on Positive Phase 3 Results for Infigrat - GuruFocus
Positive Phase III top-line results for BridgeBio’s oral infigratinib - The Pharma Letter
BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis - BioPharma Dive
BridgeBio Pharma (BBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Finviz
BridgeBio Pharma stock price target raised to $89 at Raymond James on positive trial data - Investing.com Canada
BridgeBio Pharma stock hits all-time high at 84.51 USD - Investing.com
BridgeBio Pharma Touts Strong Phase 3 PROPEL-3 Data for Oral Infigratinib in Achondroplasia - MarketBeat
BridgeBio posts trial win for dwarfism drug (BBIO:NASDAQ) - Seeking Alpha
BioMarin, Ascendis stocks fall after BridgeBio’s positive achondroplasia data By Investing.com - Investing.com Canada
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia - The Manila Times
BridgeBio stock jumps after positive Phase 3 results for achondroplasia drug - Investing.com Canada
BridgeBio Pharma Reports Positive Topline Results from PROPEL 3 Study of Oral Infigratinib in Children with Achondroplasia - Quiver Quantitative
BBIO: Oral infigratinib delivers significant growth and proportionality benefits in achondroplasia - TradingView
BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial - Reuters
BridgeBio Pharma (BBIO) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Why (BBIO) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Candriam S.C.A. Invests $7.74 Million in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma supports LGMD Family Guide distribution at conference - Traders Union
Targets Report: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEARJuly 2025 Decliners & Fast Gain Stock Trading Tips - baoquankhu1.vn
Buy the Dip on This Biotech Stock After Recent Fall - Finviz
BridgeBio Pharma (BBIO) Surges 6.8%: Is This an Indication of Further Gains? - Yahoo Finance
BridgeBio: Initiating At A Neutral Rating, Stock Priced At Perfection (NASDAQ:BBIO) - Seeking Alpha
Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO), Bristol-Myers Squibb (BMY) and Qiagen (QGEN) - The Globe and Mail
BridgeBio (BBIO) tumbles 15%, mirrors marked bleed - MSN
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap UpHere's What Happened - MarketBeat
BridgeBio (BBIO) Tumbles 15%, Mirrors Marked Bleed - Finviz
BridgeBio Pharma Enters Oversold Territory (BBIO) - Nasdaq
WCM Investment Management LLC Sells 14,253 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. $BBIO Shares Acquired by Principal Financial Group Inc. - MarketBeat
Y Intercept Hong Kong Ltd Has $724,000 Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Eyeing a 20.55% Upside Amidst Robust Revenue Growth - DirectorsTalk Interviews
Understanding Momentum Shifts in (BBIO) - Stock Traders Daily
Leerink Partners Maintains a Buy on BridgeBio Pharma (BBIO) With a $56 PT - MSN
BridgeBio Pharma, Inc. $BBIO Shares Acquired by Federated Hermes Inc. - MarketBeat
Movement Recap: Is BridgeBio Pharma Inc stock a value trapJuly 2025 Spike Watch & Comprehensive Market Scan Insights - baoquankhu1.vn
Assessing BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility - Yahoo Finance
Barclays Initiates Coverage of BridgeBio Pharma (BBIO) with Overweight Recommendation - Nasdaq
Will BridgeBio Pharma Inc. benefit from government policyGold Moves & Free Fast Gain Swing Trade Alerts - mfd.ru
BBIO Sees New Analyst Initiation with 'Overweight' Rating by Bar - GuruFocus
Barclays Initiates Coverage on BridgeBio Pharma With Overweight Rating, $157 Price Target - marketscreener.com
BridgeBio Pharma stock initiated with Overweight rating by Barclays - Investing.com Canada
Bridgebio Pharma Inc (BBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bridgebio Pharma Inc 주식 (BBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer |
Jan 08 '26 |
Sale |
73.97 |
40,000 |
2,958,855 |
735,686 |
1.24%
0.19%
자본화:
|
볼륨(24시간):